Company intelligence / Profile preview

Polfarmex

Kutno, Łódzkie, Poland

Ownership: Private
Employees: ~700
Development stage: Other

Overview

Polfarmex is a leading Polish manufacturer of generic drugs with over 100 products available in Poland, Central and Eastern Europe, the Baltics, and the Far East; since 2017, it has engaged in R&D for biosimilars, focusing particularly on insulin analogues[2][3][4].

Therapeutic areas: PsychiatryGastroenterologyDermatologyPulmonologyCardiovascularNeurologyWomen's Health
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Mabion (historical founding partner)

Beyond the preview

Go deeper on Polfarmex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polfarmex.

Explore the full profile